Prostate Cancer Diagnostics Industry Research Report 2024
Summary
The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.
According to APO Research, The global Prostate Cancer Diagnostics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
North American market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Prostate Cancer Diagnostics include OPKO, Genomic Health, Abbott, Beckman Coulter, Siemens Healthcare, bioMeriux, Roche, MDx Health and DiaSorin, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Prostate Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Prostate Cancer Diagnostics.
The Prostate Cancer Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Prostate Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prostate Cancer Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Prostate Cancer Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prostate Cancer Diagnostics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Prostate Cancer Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.
According to APO Research, The global Prostate Cancer Diagnostics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
North American market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Prostate Cancer Diagnostics include OPKO, Genomic Health, Abbott, Beckman Coulter, Siemens Healthcare, bioMeriux, Roche, MDx Health and DiaSorin, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Prostate Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Prostate Cancer Diagnostics.
The Prostate Cancer Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Prostate Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- OPKO
- Genomic Health
- Abbott
- Beckman Coulter
- Siemens Healthcare
- bioMeriux
- Roche
- MDx Health
- DiaSorin
- Myriad Genetics
- Ambry Genetics
- Tumor Biomarker Tests
- Imaging
- Biopsy
- Other
- Age Below 55
- Age 55-75
- Age Above 75
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prostate Cancer Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Prostate Cancer Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prostate Cancer Diagnostics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Prostate Cancer Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
1 PREFACE
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Prostate Cancer Diagnostics by Type
2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
2.2.2 Tumor Biomarker Tests
2.2.3 Imaging
2.2.4 Biopsy
2.2.5 Other
2.3 Prostate Cancer Diagnostics by Application
2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
2.3.2 Age Below
2.3.3 Age 55-75
2.3.4 Age Above
2.4 Assumptions and Limitations
3 PROSTATE CANCER DIAGNOSTICS BREAKDOWN DATA BY TYPE
3.1 Global Prostate Cancer Diagnostics Historic Market Size by Type (2019-2024)
3.2 Global Prostate Cancer Diagnostics Forecasted Market Size by Type (2025-2030)
4 PROSTATE CANCER DIAGNOSTICS BREAKDOWN DATA BY APPLICATION
4.1 Global Prostate Cancer Diagnostics Historic Market Size by Application (2019-2024)
4.2 Global Prostate Cancer Diagnostics Forecasted Market Size by Application (2019-2024)
5 GLOBAL GROWTH TRENDS
5.1 Global Prostate Cancer Diagnostics Market Perspective (2019-2030)
5.2 Global Prostate Cancer Diagnostics Growth Trends by Region
5.2.1 Global Prostate Cancer Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
5.2.2 Prostate Cancer Diagnostics Historic Market Size by Region (2019-2024)
5.2.3 Prostate Cancer Diagnostics Forecasted Market Size by Region (2025-2030)
5.3 Prostate Cancer Diagnostics Market Dynamics
5.3.1 Prostate Cancer Diagnostics Industry Trends
5.3.2 Prostate Cancer Diagnostics Market Drivers
5.3.3 Prostate Cancer Diagnostics Market Challenges
5.3.4 Prostate Cancer Diagnostics Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Prostate Cancer Diagnostics Players by Revenue
6.1.1 Global Top Prostate Cancer Diagnostics Players by Revenue (2019-2024)
6.1.2 Global Prostate Cancer Diagnostics Revenue Market Share by Players (2019-2024)
6.2 Global Prostate Cancer Diagnostics Industry Players Ranking, 2022 VS 2023 VS 2024
6.3 Global Key Players of Prostate Cancer Diagnostics Head office and Area Served
6.4 Global Prostate Cancer Diagnostics Players, Product Type & Application
6.5 Global Prostate Cancer Diagnostics Players, Date of Enter into This Industry
6.6 Global Prostate Cancer Diagnostics Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Prostate Cancer Diagnostics Market Size (2019-2030)
7.2 North America Prostate Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 North America Prostate Cancer Diagnostics Market Size by Country (2019-2024)
7.4 North America Prostate Cancer Diagnostics Market Size by Country (2025-2030)
7.5 United States
7.6 Canada
8 EUROPE
8.1 Europe Prostate Cancer Diagnostics Market Size (2019-2030)
8.2 Europe Prostate Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Europe Prostate Cancer Diagnostics Market Size by Country (2019-2024)
8.4 Europe Prostate Cancer Diagnostics Market Size by Country (2025-2030)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Russia
8.10 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Prostate Cancer Diagnostics Market Size (2019-2030)
9.2 Asia-Pacific Prostate Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Asia-Pacific Prostate Cancer Diagnostics Market Size by Country (2019-2024)
9.4 Asia-Pacific Prostate Cancer Diagnostics Market Size by Country (2025-2030)
9.5 China
9.6 Japan
9.7 South Korea
9.8 Southeast Asia
9.9 India
9.10 Australia
10 LATIN AMERICA
10.1 Latin America Prostate Cancer Diagnostics Market Size (2019-2030)
10.2 Latin America Prostate Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Latin America Prostate Cancer Diagnostics Market Size by Country (2019-2024)
10.4 Latin America Prostate Cancer Diagnostics Market Size by Country (2025-2030)
10.5 Mexico
10.6 Brazil
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Prostate Cancer Diagnostics Market Size (2019-2030)
11.2 Middle East & Africa Prostate Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
11.3 Middle East & Africa Prostate Cancer Diagnostics Market Size by Country (2019-2024)
11.4 Middle East & Africa Prostate Cancer Diagnostics Market Size by Country (2025-2030)
11.5 Turkey
11.6 Saudi Arabia
11.7 UAE
12 PLAYERS PROFILED
12.1 OPKO
12.1.1 OPKO Company Information
12.1.2 OPKO Business Overview
12.1.3 OPKO Revenue in Prostate Cancer Diagnostics Business (2019-2024)
12.1.4 OPKO Prostate Cancer Diagnostics Product Portfolio
12.1.5 OPKO Recent Developments
12.2 Genomic Health
12.2.1 Genomic Health Company Information
12.2.2 Genomic Health Business Overview
12.2.3 Genomic Health Revenue in Prostate Cancer Diagnostics Business (2019-2024)
12.2.4 Genomic Health Prostate Cancer Diagnostics Product Portfolio
12.2.5 Genomic Health Recent Developments
12.3 Abbott
12.3.1 Abbott Company Information
12.3.2 Abbott Business Overview
12.3.3 Abbott Revenue in Prostate Cancer Diagnostics Business (2019-2024)
12.3.4 Abbott Prostate Cancer Diagnostics Product Portfolio
12.3.5 Abbott Recent Developments
12.4 Beckman Coulter
12.4.1 Beckman Coulter Company Information
12.4.2 Beckman Coulter Business Overview
12.4.3 Beckman Coulter Revenue in Prostate Cancer Diagnostics Business (2019-2024)
12.4.4 Beckman Coulter Prostate Cancer Diagnostics Product Portfolio
12.4.5 Beckman Coulter Recent Developments
12.5 Siemens Healthcare
12.5.1 Siemens Healthcare Company Information
12.5.2 Siemens Healthcare Business Overview
12.5.3 Siemens Healthcare Revenue in Prostate Cancer Diagnostics Business (2019-2024)
12.5.4 Siemens Healthcare Prostate Cancer Diagnostics Product Portfolio
12.5.5 Siemens Healthcare Recent Developments
12.6 bioMeriux
12.6.1 bioMeriux Company Information
12.6.2 bioMeriux Business Overview
12.6.3 bioMeriux Revenue in Prostate Cancer Diagnostics Business (2019-2024)
12.6.4 bioMeriux Prostate Cancer Diagnostics Product Portfolio
12.6.5 bioMeriux Recent Developments
12.7 Roche
12.7.1 Roche Company Information
12.7.2 Roche Business Overview
12.7.3 Roche Revenue in Prostate Cancer Diagnostics Business (2019-2024)
12.7.4 Roche Prostate Cancer Diagnostics Product Portfolio
12.7.5 Roche Recent Developments
12.8 MDx Health
12.8.1 MDx Health Company Information
12.8.2 MDx Health Business Overview
12.8.3 MDx Health Revenue in Prostate Cancer Diagnostics Business (2019-2024)
12.8.4 MDx Health Prostate Cancer Diagnostics Product Portfolio
12.8.5 MDx Health Recent Developments
12.9 DiaSorin
12.9.1 DiaSorin Company Information
12.9.2 DiaSorin Business Overview
12.9.3 DiaSorin Revenue in Prostate Cancer Diagnostics Business (2019-2024)
12.9.4 DiaSorin Prostate Cancer Diagnostics Product Portfolio
12.9.5 DiaSorin Recent Developments
12.10 Myriad Genetics
12.10.1 Myriad Genetics Company Information
12.10.2 Myriad Genetics Business Overview
12.10.3 Myriad Genetics Revenue in Prostate Cancer Diagnostics Business (2019-2024)
12.10.4 Myriad Genetics Prostate Cancer Diagnostics Product Portfolio
12.10.5 Myriad Genetics Recent Developments
12.11 Ambry Genetics
12.11.1 Ambry Genetics Company Information
12.11.2 Ambry Genetics Business Overview
12.11.3 Ambry Genetics Revenue in Prostate Cancer Diagnostics Business (2019-2024)
12.11.4 Ambry Genetics Prostate Cancer Diagnostics Product Portfolio
12.11.5 Ambry Genetics Recent Developments
13 REPORT CONCLUSION
14 DISCLAIMER
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Prostate Cancer Diagnostics by Type
2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
2.2.2 Tumor Biomarker Tests
2.2.3 Imaging
2.2.4 Biopsy
2.2.5 Other
2.3 Prostate Cancer Diagnostics by Application
2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
2.3.2 Age Below
2.3.3 Age 55-75
2.3.4 Age Above
2.4 Assumptions and Limitations
3 PROSTATE CANCER DIAGNOSTICS BREAKDOWN DATA BY TYPE
3.1 Global Prostate Cancer Diagnostics Historic Market Size by Type (2019-2024)
3.2 Global Prostate Cancer Diagnostics Forecasted Market Size by Type (2025-2030)
4 PROSTATE CANCER DIAGNOSTICS BREAKDOWN DATA BY APPLICATION
4.1 Global Prostate Cancer Diagnostics Historic Market Size by Application (2019-2024)
4.2 Global Prostate Cancer Diagnostics Forecasted Market Size by Application (2019-2024)
5 GLOBAL GROWTH TRENDS
5.1 Global Prostate Cancer Diagnostics Market Perspective (2019-2030)
5.2 Global Prostate Cancer Diagnostics Growth Trends by Region
5.2.1 Global Prostate Cancer Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
5.2.2 Prostate Cancer Diagnostics Historic Market Size by Region (2019-2024)
5.2.3 Prostate Cancer Diagnostics Forecasted Market Size by Region (2025-2030)
5.3 Prostate Cancer Diagnostics Market Dynamics
5.3.1 Prostate Cancer Diagnostics Industry Trends
5.3.2 Prostate Cancer Diagnostics Market Drivers
5.3.3 Prostate Cancer Diagnostics Market Challenges
5.3.4 Prostate Cancer Diagnostics Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Prostate Cancer Diagnostics Players by Revenue
6.1.1 Global Top Prostate Cancer Diagnostics Players by Revenue (2019-2024)
6.1.2 Global Prostate Cancer Diagnostics Revenue Market Share by Players (2019-2024)
6.2 Global Prostate Cancer Diagnostics Industry Players Ranking, 2022 VS 2023 VS 2024
6.3 Global Key Players of Prostate Cancer Diagnostics Head office and Area Served
6.4 Global Prostate Cancer Diagnostics Players, Product Type & Application
6.5 Global Prostate Cancer Diagnostics Players, Date of Enter into This Industry
6.6 Global Prostate Cancer Diagnostics Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Prostate Cancer Diagnostics Market Size (2019-2030)
7.2 North America Prostate Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 North America Prostate Cancer Diagnostics Market Size by Country (2019-2024)
7.4 North America Prostate Cancer Diagnostics Market Size by Country (2025-2030)
7.5 United States
7.6 Canada
8 EUROPE
8.1 Europe Prostate Cancer Diagnostics Market Size (2019-2030)
8.2 Europe Prostate Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Europe Prostate Cancer Diagnostics Market Size by Country (2019-2024)
8.4 Europe Prostate Cancer Diagnostics Market Size by Country (2025-2030)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Russia
8.10 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Prostate Cancer Diagnostics Market Size (2019-2030)
9.2 Asia-Pacific Prostate Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Asia-Pacific Prostate Cancer Diagnostics Market Size by Country (2019-2024)
9.4 Asia-Pacific Prostate Cancer Diagnostics Market Size by Country (2025-2030)
9.5 China
9.6 Japan
9.7 South Korea
9.8 Southeast Asia
9.9 India
9.10 Australia
10 LATIN AMERICA
10.1 Latin America Prostate Cancer Diagnostics Market Size (2019-2030)
10.2 Latin America Prostate Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Latin America Prostate Cancer Diagnostics Market Size by Country (2019-2024)
10.4 Latin America Prostate Cancer Diagnostics Market Size by Country (2025-2030)
10.5 Mexico
10.6 Brazil
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Prostate Cancer Diagnostics Market Size (2019-2030)
11.2 Middle East & Africa Prostate Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
11.3 Middle East & Africa Prostate Cancer Diagnostics Market Size by Country (2019-2024)
11.4 Middle East & Africa Prostate Cancer Diagnostics Market Size by Country (2025-2030)
11.5 Turkey
11.6 Saudi Arabia
11.7 UAE
12 PLAYERS PROFILED
12.1 OPKO
12.1.1 OPKO Company Information
12.1.2 OPKO Business Overview
12.1.3 OPKO Revenue in Prostate Cancer Diagnostics Business (2019-2024)
12.1.4 OPKO Prostate Cancer Diagnostics Product Portfolio
12.1.5 OPKO Recent Developments
12.2 Genomic Health
12.2.1 Genomic Health Company Information
12.2.2 Genomic Health Business Overview
12.2.3 Genomic Health Revenue in Prostate Cancer Diagnostics Business (2019-2024)
12.2.4 Genomic Health Prostate Cancer Diagnostics Product Portfolio
12.2.5 Genomic Health Recent Developments
12.3 Abbott
12.3.1 Abbott Company Information
12.3.2 Abbott Business Overview
12.3.3 Abbott Revenue in Prostate Cancer Diagnostics Business (2019-2024)
12.3.4 Abbott Prostate Cancer Diagnostics Product Portfolio
12.3.5 Abbott Recent Developments
12.4 Beckman Coulter
12.4.1 Beckman Coulter Company Information
12.4.2 Beckman Coulter Business Overview
12.4.3 Beckman Coulter Revenue in Prostate Cancer Diagnostics Business (2019-2024)
12.4.4 Beckman Coulter Prostate Cancer Diagnostics Product Portfolio
12.4.5 Beckman Coulter Recent Developments
12.5 Siemens Healthcare
12.5.1 Siemens Healthcare Company Information
12.5.2 Siemens Healthcare Business Overview
12.5.3 Siemens Healthcare Revenue in Prostate Cancer Diagnostics Business (2019-2024)
12.5.4 Siemens Healthcare Prostate Cancer Diagnostics Product Portfolio
12.5.5 Siemens Healthcare Recent Developments
12.6 bioMeriux
12.6.1 bioMeriux Company Information
12.6.2 bioMeriux Business Overview
12.6.3 bioMeriux Revenue in Prostate Cancer Diagnostics Business (2019-2024)
12.6.4 bioMeriux Prostate Cancer Diagnostics Product Portfolio
12.6.5 bioMeriux Recent Developments
12.7 Roche
12.7.1 Roche Company Information
12.7.2 Roche Business Overview
12.7.3 Roche Revenue in Prostate Cancer Diagnostics Business (2019-2024)
12.7.4 Roche Prostate Cancer Diagnostics Product Portfolio
12.7.5 Roche Recent Developments
12.8 MDx Health
12.8.1 MDx Health Company Information
12.8.2 MDx Health Business Overview
12.8.3 MDx Health Revenue in Prostate Cancer Diagnostics Business (2019-2024)
12.8.4 MDx Health Prostate Cancer Diagnostics Product Portfolio
12.8.5 MDx Health Recent Developments
12.9 DiaSorin
12.9.1 DiaSorin Company Information
12.9.2 DiaSorin Business Overview
12.9.3 DiaSorin Revenue in Prostate Cancer Diagnostics Business (2019-2024)
12.9.4 DiaSorin Prostate Cancer Diagnostics Product Portfolio
12.9.5 DiaSorin Recent Developments
12.10 Myriad Genetics
12.10.1 Myriad Genetics Company Information
12.10.2 Myriad Genetics Business Overview
12.10.3 Myriad Genetics Revenue in Prostate Cancer Diagnostics Business (2019-2024)
12.10.4 Myriad Genetics Prostate Cancer Diagnostics Product Portfolio
12.10.5 Myriad Genetics Recent Developments
12.11 Ambry Genetics
12.11.1 Ambry Genetics Company Information
12.11.2 Ambry Genetics Business Overview
12.11.3 Ambry Genetics Revenue in Prostate Cancer Diagnostics Business (2019-2024)
12.11.4 Ambry Genetics Prostate Cancer Diagnostics Product Portfolio
12.11.5 Ambry Genetics Recent Developments
13 REPORT CONCLUSION
14 DISCLAIMER
LIST OF TABLES
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Prostate Cancer Diagnostics Market Size by Type (2018-2023) & (US$ Million)
Table 6. Global Prostate Cancer Diagnostics Revenue Market Share by Type (2018-2023)
Table 7. Global Prostate Cancer Diagnostics Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 8. Global Prostate Cancer Diagnostics Revenue Market Share by Type (2024-2029)
Table 9. Global Prostate Cancer Diagnostics Market Size by Application (2018-2023) & (US$ Million)
Table 10. Global Prostate Cancer Diagnostics Revenue Market Share by Application (2018-2023)
Table 11. Global Prostate Cancer Diagnostics Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 12. Global Prostate Cancer Diagnostics Revenue Market Share by Application (2024-2029)
Table 13. Global Prostate Cancer Diagnostics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 14. Global Prostate Cancer Diagnostics Market Size by Region (2018-2023) & (US$ Million)
Table 15. Global Prostate Cancer Diagnostics Market Share by Region (2018-2023)
Table 16. Global Prostate Cancer Diagnostics Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 17. Global Prostate Cancer Diagnostics Market Share by Region (2024-2029)
Table 18. Prostate Cancer Diagnostics Market Trends
Table 19. Prostate Cancer Diagnostics Market Drivers
Table 20. Prostate Cancer Diagnostics Market Challenges
Table 21. Prostate Cancer Diagnostics Market Restraints
Table 22. Global Top Prostate Cancer Diagnostics Manufacturers by Revenue (US$ Million) & (2018-2023)
Table 23. Global Prostate Cancer Diagnostics Revenue Market Share by Manufacturers (2018-2023)
Table 24. Global Prostate Cancer Diagnostics Industry Manufacturers Ranking, 2021 VS 2022 VS 2023
Table 25. Global Key Players of Prostate Cancer Diagnostics, Headquarters and Area Served
Table 26. Global Prostate Cancer Diagnostics Manufacturers, Product Type & Application
Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Prostate Cancer Diagnostics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. North America Prostate Cancer Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. North America Prostate Cancer Diagnostics Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America Prostate Cancer Diagnostics Market Size by Country (2024-2029) & (US$ Million)
Table 33. Europe Prostate Cancer Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 34. Europe Prostate Cancer Diagnostics Market Size by Country (2018-2023) & (US$ Million)
Table 35. Europe Prostate Cancer Diagnostics Market Size by Country (2024-2029) & (US$ Million)
Table 36. Asia-Pacific Prostate Cancer Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 37. Asia-Pacific Prostate Cancer Diagnostics Market Size by Country (2018-2023) & (US$ Million)
Table 38. Asia-Pacific Prostate Cancer Diagnostics Market Size by Country (2024-2029) & (US$ Million)
Table 39. Latin America Prostate Cancer Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 40. Latin America Prostate Cancer Diagnostics Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Prostate Cancer Diagnostics Market Size by Country (2024-2029) & (US$ Million)
Table 42. Middle East & Africa Prostate Cancer Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 43. Middle East & Africa Prostate Cancer Diagnostics Market Size by Country (2018-2023) & (US$ Million)
Table 44. Middle East & Africa Prostate Cancer Diagnostics Market Size by Country (2024-2029) & (US$ Million)
Table 45. OPKO Company Detail
Table 46. OPKO Business Overview
Table 47. OPKO Prostate Cancer Diagnostics Product
Table 48. OPKO Revenue in Prostate Cancer Diagnostics Business (2017-2022) & (US$ Million)
Table 49. OPKO Recent Development
Table 50. Genomic Health Company Detail
Table 51. Genomic Health Business Overview
Table 52. Genomic Health Prostate Cancer Diagnostics Product
Table 53. Genomic Health Revenue in Prostate Cancer Diagnostics Business (2017-2022) & (US$ Million)
Table 54. Genomic Health Recent Development
Table 55. Abbott Company Detail
Table 56. Abbott Business Overview
Table 57. Abbott Prostate Cancer Diagnostics Product
Table 58. Abbott Revenue in Prostate Cancer Diagnostics Business (2017-2022) & (US$ Million)
Table 59. Abbott Recent Development
Table 60. Beckman Coulter Company Detail
Table 61. Beckman Coulter Business Overview
Table 62. Beckman Coulter Prostate Cancer Diagnostics Product
Table 63. Beckman Coulter Revenue in Prostate Cancer Diagnostics Business (2017-2022) & (US$ Million)
Table 64. Beckman Coulter Recent Development
Table 65. Siemens Healthcare Company Detail
Table 66. Siemens Healthcare Business Overview
Table 67. Siemens Healthcare Prostate Cancer Diagnostics Product
Table 68. Siemens Healthcare Revenue in Prostate Cancer Diagnostics Business (2017-2022) & (US$ Million)
Table 69. Siemens Healthcare Recent Development
Table 70. bioMeriux Company Detail
Table 71. bioMeriux Business Overview
Table 72. bioMeriux Prostate Cancer Diagnostics Product
Table 73. bioMeriux Revenue in Prostate Cancer Diagnostics Business (2017-2022) & (US$ Million)
Table 74. bioMeriux Recent Development
Table 75. Roche Company Detail
Table 76. Roche Business Overview
Table 77. Roche Prostate Cancer Diagnostics Product
Table 78. Roche Revenue in Prostate Cancer Diagnostics Business (2017-2022) & (US$ Million)
Table 79. Roche Recent Development
Table 80. MDx Health Company Detail
Table 81. MDx Health Business Overview
Table 82. MDx Health Prostate Cancer Diagnostics Product
Table 83. MDx Health Revenue in Prostate Cancer Diagnostics Business (2017-2022) & (US$ Million)
Table 84. MDx Health Recent Development
Table 85. DiaSorin Company Detail
Table 86. DiaSorin Business Overview
Table 87. DiaSorin Prostate Cancer Diagnostics Product
Table 88. DiaSorin Revenue in Prostate Cancer Diagnostics Business (2017-2022) & (US$ Million)
Table 89. DiaSorin Recent Development
Table 90. Myriad Genetics Company Detail
Table 91. Myriad Genetics Business Overview
Table 92. Myriad Genetics Prostate Cancer Diagnostics Product
Table 93. Myriad Genetics Revenue in Prostate Cancer Diagnostics Business (2017-2022) & (US$ Million)
Table 94. Myriad Genetics Recent Development
Table 95. Ambry Genetics Company Detail
Table 96. Ambry Genetics Business Overview
Table 97. Ambry Genetics Prostate Cancer DiagnosticsProduct
Table 98. Ambry Genetics Revenue in Prostate Cancer Diagnostics Business (2017-2022) & (US$ Million)
Table 99. Ambry Genetics Recent Development
Table 100. OPKO Company Information
Table 101. OPKO Business Overview
Table 102. OPKO Prostate Cancer Diagnostics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million)
Table 103. OPKO Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million) Portfolio
Table 104. OPKO Recent Development
Table 105. Genomic Health Company Information
Table 106. Genomic Health Business Overview
Table 107. Genomic Health Prostate Cancer Diagnostics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million)
Table 108. Genomic Health Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million) Portfolio
Table 109. Genomic Health Recent Development
Table 110. Abbott Company Information
Table 111. Abbott Business Overview
Table 112. Abbott Prostate Cancer Diagnostics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million)
Table 113. Abbott Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million) Portfolio
Table 114. Abbott Recent Development
Table 115. Beckman Coulter Company Information
Table 116. Beckman Coulter Business Overview
Table 117. Beckman Coulter Prostate Cancer Diagnostics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million)
Table 118. Beckman Coulter Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million) Portfolio
Table 119. Beckman Coulter Recent Development
Table 120. Siemens Healthcare Company Information
Table 121. Siemens Healthcare Business Overview
Table 122. Siemens Healthcare Prostate Cancer Diagnostics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million)
Table 123. Siemens Healthcare Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million) Portfolio
Table 124. Siemens Healthcare Recent Development
Table 125. bioMeriux Company Information
Table 126. bioMeriux Business Overview
Table 127. bioMeriux Prostate Cancer Diagnostics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million)
Table 128. bioMeriux Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million) Portfolio
Table 129. bioMeriux Recent Development
Table 130. Roche Company Information
Table 131. Roche Business Overview
Table 132. Roche Prostate Cancer Diagnostics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million)
Table 133. Roche Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million) Portfolio
Table 134. Roche Recent Development
Table 135. MDx Health Company Information
Table 136. MDx Health Business Overview
Table 137. MDx Health Prostate Cancer Diagnostics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million)
Table 138. MDx Health Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million) Portfolio
Table 139. MDx Health Recent Development
Table 140. DiaSorin Company Information
Table 141. DiaSorin Business Overview
Table 142. DiaSorin Prostate Cancer Diagnostics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million)
Table 143. DiaSorin Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million) Portfolio
Table 144. DiaSorin Recent Development
Table 145. Myriad Genetics Company Information
Table 146. Myriad Genetics Business Overview
Table 147. Myriad Genetics Prostate Cancer Diagnostics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million)
Table 148. Myriad Genetics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million) Portfolio
Table 149. Myriad Genetics Recent Development
Table 150. Ambry Genetics Company Information
Table 151. Ambry Genetics Business Overview
Table 152. Ambry Genetics Prostate Cancer DiagnosticsRevenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million)
Table 153. Ambry Genetics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million) Portfolio
Table 154. Ambry Genetics Recent Development
Table 155. Authors List of This Report
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Prostate Cancer Diagnostics Market Size by Type (2018-2023) & (US$ Million)
Table 6. Global Prostate Cancer Diagnostics Revenue Market Share by Type (2018-2023)
Table 7. Global Prostate Cancer Diagnostics Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 8. Global Prostate Cancer Diagnostics Revenue Market Share by Type (2024-2029)
Table 9. Global Prostate Cancer Diagnostics Market Size by Application (2018-2023) & (US$ Million)
Table 10. Global Prostate Cancer Diagnostics Revenue Market Share by Application (2018-2023)
Table 11. Global Prostate Cancer Diagnostics Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 12. Global Prostate Cancer Diagnostics Revenue Market Share by Application (2024-2029)
Table 13. Global Prostate Cancer Diagnostics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 14. Global Prostate Cancer Diagnostics Market Size by Region (2018-2023) & (US$ Million)
Table 15. Global Prostate Cancer Diagnostics Market Share by Region (2018-2023)
Table 16. Global Prostate Cancer Diagnostics Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 17. Global Prostate Cancer Diagnostics Market Share by Region (2024-2029)
Table 18. Prostate Cancer Diagnostics Market Trends
Table 19. Prostate Cancer Diagnostics Market Drivers
Table 20. Prostate Cancer Diagnostics Market Challenges
Table 21. Prostate Cancer Diagnostics Market Restraints
Table 22. Global Top Prostate Cancer Diagnostics Manufacturers by Revenue (US$ Million) & (2018-2023)
Table 23. Global Prostate Cancer Diagnostics Revenue Market Share by Manufacturers (2018-2023)
Table 24. Global Prostate Cancer Diagnostics Industry Manufacturers Ranking, 2021 VS 2022 VS 2023
Table 25. Global Key Players of Prostate Cancer Diagnostics, Headquarters and Area Served
Table 26. Global Prostate Cancer Diagnostics Manufacturers, Product Type & Application
Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Prostate Cancer Diagnostics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. North America Prostate Cancer Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. North America Prostate Cancer Diagnostics Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America Prostate Cancer Diagnostics Market Size by Country (2024-2029) & (US$ Million)
Table 33. Europe Prostate Cancer Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 34. Europe Prostate Cancer Diagnostics Market Size by Country (2018-2023) & (US$ Million)
Table 35. Europe Prostate Cancer Diagnostics Market Size by Country (2024-2029) & (US$ Million)
Table 36. Asia-Pacific Prostate Cancer Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 37. Asia-Pacific Prostate Cancer Diagnostics Market Size by Country (2018-2023) & (US$ Million)
Table 38. Asia-Pacific Prostate Cancer Diagnostics Market Size by Country (2024-2029) & (US$ Million)
Table 39. Latin America Prostate Cancer Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 40. Latin America Prostate Cancer Diagnostics Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Prostate Cancer Diagnostics Market Size by Country (2024-2029) & (US$ Million)
Table 42. Middle East & Africa Prostate Cancer Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 43. Middle East & Africa Prostate Cancer Diagnostics Market Size by Country (2018-2023) & (US$ Million)
Table 44. Middle East & Africa Prostate Cancer Diagnostics Market Size by Country (2024-2029) & (US$ Million)
Table 45. OPKO Company Detail
Table 46. OPKO Business Overview
Table 47. OPKO Prostate Cancer Diagnostics Product
Table 48. OPKO Revenue in Prostate Cancer Diagnostics Business (2017-2022) & (US$ Million)
Table 49. OPKO Recent Development
Table 50. Genomic Health Company Detail
Table 51. Genomic Health Business Overview
Table 52. Genomic Health Prostate Cancer Diagnostics Product
Table 53. Genomic Health Revenue in Prostate Cancer Diagnostics Business (2017-2022) & (US$ Million)
Table 54. Genomic Health Recent Development
Table 55. Abbott Company Detail
Table 56. Abbott Business Overview
Table 57. Abbott Prostate Cancer Diagnostics Product
Table 58. Abbott Revenue in Prostate Cancer Diagnostics Business (2017-2022) & (US$ Million)
Table 59. Abbott Recent Development
Table 60. Beckman Coulter Company Detail
Table 61. Beckman Coulter Business Overview
Table 62. Beckman Coulter Prostate Cancer Diagnostics Product
Table 63. Beckman Coulter Revenue in Prostate Cancer Diagnostics Business (2017-2022) & (US$ Million)
Table 64. Beckman Coulter Recent Development
Table 65. Siemens Healthcare Company Detail
Table 66. Siemens Healthcare Business Overview
Table 67. Siemens Healthcare Prostate Cancer Diagnostics Product
Table 68. Siemens Healthcare Revenue in Prostate Cancer Diagnostics Business (2017-2022) & (US$ Million)
Table 69. Siemens Healthcare Recent Development
Table 70. bioMeriux Company Detail
Table 71. bioMeriux Business Overview
Table 72. bioMeriux Prostate Cancer Diagnostics Product
Table 73. bioMeriux Revenue in Prostate Cancer Diagnostics Business (2017-2022) & (US$ Million)
Table 74. bioMeriux Recent Development
Table 75. Roche Company Detail
Table 76. Roche Business Overview
Table 77. Roche Prostate Cancer Diagnostics Product
Table 78. Roche Revenue in Prostate Cancer Diagnostics Business (2017-2022) & (US$ Million)
Table 79. Roche Recent Development
Table 80. MDx Health Company Detail
Table 81. MDx Health Business Overview
Table 82. MDx Health Prostate Cancer Diagnostics Product
Table 83. MDx Health Revenue in Prostate Cancer Diagnostics Business (2017-2022) & (US$ Million)
Table 84. MDx Health Recent Development
Table 85. DiaSorin Company Detail
Table 86. DiaSorin Business Overview
Table 87. DiaSorin Prostate Cancer Diagnostics Product
Table 88. DiaSorin Revenue in Prostate Cancer Diagnostics Business (2017-2022) & (US$ Million)
Table 89. DiaSorin Recent Development
Table 90. Myriad Genetics Company Detail
Table 91. Myriad Genetics Business Overview
Table 92. Myriad Genetics Prostate Cancer Diagnostics Product
Table 93. Myriad Genetics Revenue in Prostate Cancer Diagnostics Business (2017-2022) & (US$ Million)
Table 94. Myriad Genetics Recent Development
Table 95. Ambry Genetics Company Detail
Table 96. Ambry Genetics Business Overview
Table 97. Ambry Genetics Prostate Cancer DiagnosticsProduct
Table 98. Ambry Genetics Revenue in Prostate Cancer Diagnostics Business (2017-2022) & (US$ Million)
Table 99. Ambry Genetics Recent Development
Table 100. OPKO Company Information
Table 101. OPKO Business Overview
Table 102. OPKO Prostate Cancer Diagnostics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million)
Table 103. OPKO Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million) Portfolio
Table 104. OPKO Recent Development
Table 105. Genomic Health Company Information
Table 106. Genomic Health Business Overview
Table 107. Genomic Health Prostate Cancer Diagnostics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million)
Table 108. Genomic Health Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million) Portfolio
Table 109. Genomic Health Recent Development
Table 110. Abbott Company Information
Table 111. Abbott Business Overview
Table 112. Abbott Prostate Cancer Diagnostics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million)
Table 113. Abbott Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million) Portfolio
Table 114. Abbott Recent Development
Table 115. Beckman Coulter Company Information
Table 116. Beckman Coulter Business Overview
Table 117. Beckman Coulter Prostate Cancer Diagnostics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million)
Table 118. Beckman Coulter Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million) Portfolio
Table 119. Beckman Coulter Recent Development
Table 120. Siemens Healthcare Company Information
Table 121. Siemens Healthcare Business Overview
Table 122. Siemens Healthcare Prostate Cancer Diagnostics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million)
Table 123. Siemens Healthcare Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million) Portfolio
Table 124. Siemens Healthcare Recent Development
Table 125. bioMeriux Company Information
Table 126. bioMeriux Business Overview
Table 127. bioMeriux Prostate Cancer Diagnostics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million)
Table 128. bioMeriux Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million) Portfolio
Table 129. bioMeriux Recent Development
Table 130. Roche Company Information
Table 131. Roche Business Overview
Table 132. Roche Prostate Cancer Diagnostics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million)
Table 133. Roche Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million) Portfolio
Table 134. Roche Recent Development
Table 135. MDx Health Company Information
Table 136. MDx Health Business Overview
Table 137. MDx Health Prostate Cancer Diagnostics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million)
Table 138. MDx Health Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million) Portfolio
Table 139. MDx Health Recent Development
Table 140. DiaSorin Company Information
Table 141. DiaSorin Business Overview
Table 142. DiaSorin Prostate Cancer Diagnostics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million)
Table 143. DiaSorin Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million) Portfolio
Table 144. DiaSorin Recent Development
Table 145. Myriad Genetics Company Information
Table 146. Myriad Genetics Business Overview
Table 147. Myriad Genetics Prostate Cancer Diagnostics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million)
Table 148. Myriad Genetics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million) Portfolio
Table 149. Myriad Genetics Recent Development
Table 150. Ambry Genetics Company Information
Table 151. Ambry Genetics Business Overview
Table 152. Ambry Genetics Prostate Cancer DiagnosticsRevenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million)
Table 153. Ambry Genetics Revenue in Prostate Cancer Diagnostics Business (2018-2023) & (US$ Million) Portfolio
Table 154. Ambry Genetics Recent Development
Table 155. Authors List of This Report
LIST OF FIGURES
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Prostate Cancer Diagnostics Product Picture
Figure 5. Global Prostate Cancer Diagnostics Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 6. Global Prostate Cancer Diagnostics Market Share by Type: 2022 VS 2029
Figure 7. Tumor Biomarker Tests Product Picture
Figure 8. Imaging Product Picture
Figure 9. Biopsy Product Picture
Figure 10. Other Product Picture
Figure 11. Global Prostate Cancer Diagnostics Market Size by Application (2023-2029) & (US$ Million)
Figure 12. Global Prostate Cancer Diagnostics Market Share by Application: 2022 VS 2029
Figure 13. Age Below 55 Product Picture
Figure 14. Age 55-75 Product Picture
Figure 15. Age Above 75 Product Picture
Figure 16. Global Prostate Cancer Diagnostics Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 17. Global Prostate Cancer Diagnostics Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 18. Global Prostate Cancer Diagnostics Market Share by Region: 2022 VS 2029
Figure 19. Global Prostate Cancer Diagnostics Market Share by Players in 2022
Figure 20. Global Prostate Cancer Diagnostics Players, Date of Enter into This Industry
Figure 21. Global Top 5 and 10 Prostate Cancer Diagnostics Players Market Share by Revenue in 2022
Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 23. North America Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. North America Prostate Cancer Diagnostics Market Share by Country (2018-2029)
Figure 25. United States Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Canada Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Europe Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Europe Prostate Cancer Diagnostics Market Share by Country (2018-2029)
Figure 29. Germany Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. France Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. U.K. Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Italy Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Russia Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Nordic Countries Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Asia-Pacific Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Asia-Pacific Prostate Cancer Diagnostics Market Share by Country (2018-2029)
Figure 37. China Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Japan Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. South Korea Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Southeast Asia Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. India Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Australia Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Latin America Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Latin America Prostate Cancer Diagnostics Market Share by Country (2018-2029)
Figure 45. Mexico Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Brazil Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Middle East & Africa Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Middle East & Africa Prostate Cancer Diagnostics Market Share by Country (2018-2029)
Figure 49. Turkey Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 50. Saudi Arabia Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 51. UAE Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. OPKO Revenue Growth Rate in Prostate Cancer Diagnostics Business (2018-2023)
Figure 53. Genomic Health Revenue Growth Rate in Prostate Cancer Diagnostics Business (2018-2023)
Figure 54. Abbott Revenue Growth Rate in Prostate Cancer Diagnostics Business (2018-2023)
Figure 55. Beckman Coulter Revenue Growth Rate in Prostate Cancer Diagnostics Business (2018-2023)
Figure 56. Siemens Healthcare Revenue Growth Rate in Prostate Cancer Diagnostics Business (2018-2023)
Figure 57. bioMeriux Revenue Growth Rate in Prostate Cancer Diagnostics Business (2018-2023)
Figure 58. Roche Revenue Growth Rate in Prostate Cancer Diagnostics Business (2018-2023)
Figure 59. MDx Health Revenue Growth Rate in Prostate Cancer Diagnostics Business (2018-2023)
Figure 60. DiaSorin Revenue Growth Rate in Prostate Cancer Diagnostics Business (2018-2023)
Figure 61. Myriad Genetics Revenue Growth Rate in Prostate Cancer Diagnostics Business (2018-2023)
Figure 62. Ambry Genetics Revenue Growth Rate in Prostate Cancer Diagnostics Business (2018-2023)
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Prostate Cancer Diagnostics Product Picture
Figure 5. Global Prostate Cancer Diagnostics Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 6. Global Prostate Cancer Diagnostics Market Share by Type: 2022 VS 2029
Figure 7. Tumor Biomarker Tests Product Picture
Figure 8. Imaging Product Picture
Figure 9. Biopsy Product Picture
Figure 10. Other Product Picture
Figure 11. Global Prostate Cancer Diagnostics Market Size by Application (2023-2029) & (US$ Million)
Figure 12. Global Prostate Cancer Diagnostics Market Share by Application: 2022 VS 2029
Figure 13. Age Below 55 Product Picture
Figure 14. Age 55-75 Product Picture
Figure 15. Age Above 75 Product Picture
Figure 16. Global Prostate Cancer Diagnostics Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 17. Global Prostate Cancer Diagnostics Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 18. Global Prostate Cancer Diagnostics Market Share by Region: 2022 VS 2029
Figure 19. Global Prostate Cancer Diagnostics Market Share by Players in 2022
Figure 20. Global Prostate Cancer Diagnostics Players, Date of Enter into This Industry
Figure 21. Global Top 5 and 10 Prostate Cancer Diagnostics Players Market Share by Revenue in 2022
Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 23. North America Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. North America Prostate Cancer Diagnostics Market Share by Country (2018-2029)
Figure 25. United States Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Canada Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Europe Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Europe Prostate Cancer Diagnostics Market Share by Country (2018-2029)
Figure 29. Germany Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. France Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. U.K. Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Italy Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Russia Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Nordic Countries Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Asia-Pacific Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Asia-Pacific Prostate Cancer Diagnostics Market Share by Country (2018-2029)
Figure 37. China Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Japan Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. South Korea Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Southeast Asia Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. India Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Australia Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Latin America Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Latin America Prostate Cancer Diagnostics Market Share by Country (2018-2029)
Figure 45. Mexico Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Brazil Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Middle East & Africa Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Middle East & Africa Prostate Cancer Diagnostics Market Share by Country (2018-2029)
Figure 49. Turkey Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 50. Saudi Arabia Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 51. UAE Prostate Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. OPKO Revenue Growth Rate in Prostate Cancer Diagnostics Business (2018-2023)
Figure 53. Genomic Health Revenue Growth Rate in Prostate Cancer Diagnostics Business (2018-2023)
Figure 54. Abbott Revenue Growth Rate in Prostate Cancer Diagnostics Business (2018-2023)
Figure 55. Beckman Coulter Revenue Growth Rate in Prostate Cancer Diagnostics Business (2018-2023)
Figure 56. Siemens Healthcare Revenue Growth Rate in Prostate Cancer Diagnostics Business (2018-2023)
Figure 57. bioMeriux Revenue Growth Rate in Prostate Cancer Diagnostics Business (2018-2023)
Figure 58. Roche Revenue Growth Rate in Prostate Cancer Diagnostics Business (2018-2023)
Figure 59. MDx Health Revenue Growth Rate in Prostate Cancer Diagnostics Business (2018-2023)
Figure 60. DiaSorin Revenue Growth Rate in Prostate Cancer Diagnostics Business (2018-2023)
Figure 61. Myriad Genetics Revenue Growth Rate in Prostate Cancer Diagnostics Business (2018-2023)
Figure 62. Ambry Genetics Revenue Growth Rate in Prostate Cancer Diagnostics Business (2018-2023)
